chartexchange

BlossomHill Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights

GlobeNewswire Inc. | Nov 12, 2026 4:01 PM EST

Alignment with the US Food and Drug Administration (FDA) on 50 mg twice daily as the recommended Phase 2 dose for BH-30643 based on favorable PK, safety, and efficacy data to date

Read original article